



UNITED STATES ENVIRONMENTAL PROTECTION AGENCY

WASHINGTON, D.C. 20460

MAR 15 1989

007074

MAR 15 1989

DATE
RECEIVED
TIME

MEMORANDUM

SUBJECT: EPA Identification No. 476-EEEE;
SC-0224 4-LO (Containing 39.9% Sulfosate);
Registration for Noncrop Uses Around the Farm

Tox Chem No. 893C
Project No. 9-0414
Record No. 235,371

FROM: Edwin R. Briff, Section Head
Review Section I, Toxicology Branch-I (IRS)
Health Effects Division (H7509C)

TO: Robert J. Taylor, PM 25
Fungicide-Herbicide Branch
Registration Division (H7505C)

THRU: Judith W. Hanswirth, Chief
Toxicology Branch-I (IPS)
Health Effects Division (H7509C)

Requested Action:

ICI Americas, Inc. has requested registration of SC-0224 4-LO (also known as Touchdown 4-LO), containing 39.9% sulfosate as the active ingredient, for weed control in noncrop areas around the farm. Sulfosate is a new (i.e. not previously registered), nonselective foliar systemic herbicide.

This is an amended request for registration in that registration was previously sought for a similar end-use product but identified as SC-1224 (or Touchdown 4-LO). The end-use product for which registration is presently sought contains a different surfactant than the 4-LO formulation and is identified more precisely as SC-0224 (or Touchdown 4-LO). Based on a set of acute toxicity studies conducted on the 4-LO formulation and submitted in this package in support of the present request, the 4-LO formulation is less toxic, on an acute basis, than the 4-LO formulation. Hereafter, in this review, the 4-LO formulation for which registration is being sought will be referred to as the 4-LO formulation, unless specifically noted otherwise.

BEST COPY AVAILABLE

1/15/89

Recommendation:

Sufficient toxicological information and studies have been submitted to support conditional registration of this end-use product and Toxicology Branch-I (TB-I) has no objection to conditional registration of this product at this time, provided that the applicant agrees to submit in the near future suitable responses to the deficiencies and concerns listed below.

Based on an overall evaluation of the totality of toxicological information presently available on sulfosate, including several acute studies on the 4-LC end-use product, the proposed use of SC-1224 4-LC for weed control in noncrop areas around the farm is not considered by TB-I to present a significant toxicological hazard to persons exposed to the product. These studies include acute toxicity studies on several similar products, a subchronicermal study on rabbits, teratology studies on rats and rabbits, reproduction and fertility studies on rats, chronic feeding studies on dogs and rats, oncogenic studies on mice and rats, metabolism data and numerous mutagenicity studies. Although not all these studies are fully acceptable at this time, there is nevertheless ample toxicological information to fully support this conditional registration for noncrop use.

On the other hand, certain toxicity studies required to support full registration of this end-use product are not satisfactorily completed or are not available at this time, hence the recommendation for a conditional registration. The specific study deficiencies (data gaps) are:

1 - an acute inhalation LC₅₀ study on the SC-1224 4-LC formulation (see item 1 below), and

2 - a 21-dayermal study on the SC-1224 4-LC formulation (see item 2 below).

It is not anticipated that submission of these studies at a later date will affect the regulatory status of this end-use product in any significant way. Nevertheless, these two studies should be performed and submitted to the Agency in the near future to complete the toxicity data base required for full registration of this product and to fully confirm that use of this product will not present an unreasonable hazard to persons exposed to it.

BEST AVAILABLE COPY

Comments:

1. An unsuccessful attempt to perform an acute inhalation LC50 study on the 4-LO end-use product was reported in this package (Stauffer Chemical Co., No. T-12983, 6/22/87). The authors stated that "it was not possible to generate a respirable aerosol. Repeated attempts at generating an aerosol were unsuccessful due to the high viscosity and foaming properties of SC-0224 4LO-E.---(and therefore) the formulation evaluated does not pose an inhalation hazard because a respirable aerosol could not be generated." IR-1 does not concur with this viewpoint at this time and believes "that certain additional effort should be directed toward the evaluation of the test material for inhalation toxicity. The Registrant should be advised to pursue additional testing taking into advisement the following suggestions:

- 1) Dilute the SC-0224 4LO-E (40% a.i.) with [REDACTED] until foaming stops.
- 2) Reduce surfactants until foaming stops.
- 3) If necessary, form a dense fog and run through a cyclone separator to remove large particles.
- 4) Consult with Toxicology Branch if testing problems continue." (from review of this study by Dr. Brian Demetri, attached).

2. The applicant has requested a waiver of the previously required 21-day dermal study to be performed on the 4-LO end-use product. The applicant believes that this study is not necessary for the following reasons:

"The formulation is of low acute dermal toxicity.

We have replaced the formulation previously proposed for use, the 4LCB formulation, (Toxicity Category I) with the 4LCE formulation, (Toxicity Category III).

The active ingredient is of low subchronic dermal toxicity.

We have completed a 21-day dermal study with SC-0224 Concentrate (57.3% active) (EPA File Symbol 476-ZEEL). In all respects, including food consumption, hematology, blood chemistry and organ weights, rabbits treated with sulfosate showed no biologically

NEED INDEPENDENT INFORMATION IS NOT INCLUDED

BEST AVAILABLE COPY

3

significant treatment-related effects. It was concluded that sulfosate is of low systemic toxicity on repeated dermal applications to the abraded and nonabraded skin of the male and female rabbit. The no-effect level was considered to be 1000 mg/kg/day.

Thus further testing of the 4-LOE formulation which contains 39.9% active is unlikely to provide additional information and would be a wasteful use of experimental animals and contrary to the Agency's policy of reducing the use of experimental animals."

TS-1 does not agree that this study is not necessary and recommends that the study be required to be submitted to the Agency. TS-1 would have no objection, however, to the study being submitted following conditional registration of the 4-LOE product.

The rationale for this determination is based on the differences in product composition between the aqueous SC-0224 Concentrate, for which a 21-day dermal study has already been conducted (see above), and the SC-0224 4-LOE which contains about 40% surfactant. The presence of surfactant in the latter product is likely to substantially increase dermal absorption of the formulation and/or active ingredient and possibly produce greater dermal irritation and/or greater systemic toxicity than for the concentrate, particularly following repeated dermal applications. Inasmuch as mild dermal irritation (erythema) was observed in all treated groups in the 21-day dermal study on the concentrate (at doses as low as 10 mg/kg/day, LDF), it is possible that increased irritation and/or systemic toxicity might occur in a 21-day dermal study on the 4-LOE product or at dose levels below which similar effects were observed in the first study. For reasons described above under Recommendations, however, this study may be submitted at a later time--in order to complete the toxicity data base for full registration and to fully confirm the lack of unreasonable hazard to persons exposed to the product.

3. The applicant has submitted in this package six acute toxicity studies on SC-0224 4-LOE, which are to be differentiated from acute toxicity studies previously submitted on SC-0224 4-LOE. With the exception of the acute inhalation toxicity study (which was discussed above in 1. and which is classified as Core-Supplementary), all of the remaining five studies are classified as Core-Guideline. The results of these studies are summarized below:

- 1) Acute oral toxicity study, rats
LD₅₀ (males) = 1760 mg/kg
LD₅₀ (females) = 1298 mg/kg
Toxicity Category III

INERT INGREDIENT INFORMATION IS NOT INCLUDED

4

- 2) Acute dermal toxicity study, rabbits
LD₅₀ (males/females) >2000 mg/kg
Toxicity Category III
- 3) Dermal irritation study, rabbits
non-irritating (4 hour exposure)
Toxicity Category IV
- 4) Eye irritation study, rabbits
moderate irritation, clearing by day 7
Toxicity Category III
- 5) Skin sensitization study, guinea pigs
negative in modified Buehler test

The TB-I reviews of these acute toxicity studies, by Dr. Brian Dementi, are attached.

4. The proposed label (attached) for this Toxicity Category III product is acceptable provided that the following changes are made:

- 1) On page 1, add the following to the statement of practical treatment (as on the TB-I approved label for SC-0224 Concentrate, EPA Identification No. 476-EHEL):

"If on Skin, Flush with plenty of water for at least 15 minutes. Remove contaminated clothing and shoes. Get medical attention if skin irritation occurs. Wash clothing before re-use."

"If Inhaled, Remove to fresh air. Seek medical attention if respiratory irritation occurs or if breathing becomes difficult."

- 2) On page 2, the precautionary statements paragraph should be modified so as to be exactly the same as for the TB-I approved label for SC-0224 Concentrate, EPA Identification No. 476-EHEL).

"HARMFUL IF SWALLOWED, ABSORBED THROUGH THE SKIN OR INHALED. PROLONGED CONTACT MAY CAUSE SKIN IRRITATION. MAY CAUSE ALLERGIC SKIN REACTIONS. Avoid contact with skin, eyes or clothing. Wear rubber gloves when handling. Avoid breathing spray mist."

Wash thoroughly with soap and water after handling and before eating or smoking. Remove contaminated clothing and wash before re-use."

007074

6

- 3) On page 5, all references to the mixing of this product with a surfactant should be deleted.

Attachments

6

Tof Review 007074

Page _____ is not included in this copy.

Pages 7 through 13 are not included.

The material not included contains the following type of information:

- ☐ Identity of product inert ingredients.
- ☐ Identity of product impurities.
- ☐ Description of the product manufacturing process.
- ☐ Description of quality control procedures.
- ☐ Identity of the source of product ingredients.
- ☐ Sales or other commercial/financial information.
- ☒ A draft product label.
- ☐ The product confidential statement of formula.
- ☐ Information about a pending registration action.
- ☐ FIFRA registration data.
- ☐ The document is a duplicate of page(s) _____.
- ☐ The document is not responsive to the request.

The information not included is generally considered confidential by product registrants. If you have any questions, please contact the individual who prepared the response to your request.

Reviewed by: Brian DeWitt, Ph.D., F.A.P.T.
Section 1, Toxicology Branch I - IPS (TS-7500)
Secondary Reviewer: Edwin F. Budd, Section Head
Section 1, Toxicology Branch I - IPS (TS-7500)

3/6/87
6074
Budd
3/6/87

DATA EVALUATION REPORT

Study Type: Acute studies
TOX Chem No.: 8030
Appraisal No.: 40886-02
EPA ID No.: 474-PPFA
Test Material: Sulfosate (Touchdown AIC-F Formulation)
Synonyms (Technical Active Ingredient): N-Phosphorovesbvl glycine
crystalline sulfonate salt:
SC-022-

Study Number: T-10589
Sponsor: ICI Americas, Inc.

Testing Facility: Stauffer Chemical Company
Richmond Toxicology Laboratory
Richmond, CA

Title of Report: "Acute Toxicity Tests For SC-0224 AIC-F"

Author(s): P.L. Morgan

Report Issued: February 12, 1987

Classification: Core-Guideline

Conclusions:

I. Acute Oral Toxicity (Rat)

Male LD₅₀ = 1760 mg/kg; Female LD₅₀ = 3298 mg/kg;
Toxicity Category III

II. Acute Dermal Toxicity

Mixed sexer rabbit: LD₅₀ = 2000 mg/kg;
Toxicity Category III

III. Dermal Irritation Study

Nonirritating to intact skin of the rabbit;
Toxicity Category IV

BEST AVAILABLE COPY

14

007074

III. Ocular Irritation

In the washed eyes of rabbits the test material elicited mild to moderate conjunctival irritation, which cleared by day 1. In unwashed eyes the test material produced moderate iriditis in one rabbit and mild to moderate conjunctival irritation in all six rabbits under study. All such effects cleared by day 7.

Toxicity Category # III

BEST AVAILABLE COPY

15

007674

1. Acute Oral Toxicity Tests - Fat

Mice (Sprague-Dawley albino rats) were obtained from Charles River Laboratories. Sixty male and 60 female rats were employed where 15 rats of each sex received test material and 15 of each sex served as controls. The body weight for males used in the study was 180 to 220 g and for females, 160 to 210 g. Each dose of the test material was prepared by dissolving/suspending the appropriately weighed amount in water, which vehicle served as the vehicle. Testing was performed by oral gavage by a single administration. A minimum of five males and five females were used at each dose tested. The animals were fasted for 12 to 16 hours prior to treatment. The rats were observed for at least 14 days posttreatment for mortality and signs of toxicity. Necropsies were performed on all rats.

The following tabulates the level of mortality which occurred at each dose.

Dose (mg/kg)	Mortality	
	Males (%)	Females (%)
5000	5/5 (100)	5/5 (100)
2500	4/5 (80)	5/5 (100)
1000	6/10 (60)	2/5 (40)
500	2/5 (40)	3/5 (60)
250	2/5 (40)	3/5 (60)
125	0/5 (0)	1/5 (20)

*Test solutions administered at a dosage volume to body weight ratio (ml/kg) of 10.

Not shown in the tabulation were 15 male and 15 female rats administered water as vehicle control, which were without mortality.

In inspection of a plot of the above data it was determined that for male rats, 1000 = LD50 mg/kg and for females, 1000 = LD50 mg/kg.

A review of the description of clinical signs and necropsy results at each dose (pages 15 to 17 for males and 18 to 20 for females) confirms the statements of the study author that the effect of the test material, the only controls observed adverse clinical sign was depression. In addition, observations included darkened livers, darkened spleens, test-like material in the stomach or GI tract, and pale testes. For females there were no clinically observed clinical signs. There was some evidence of rough coats.

16

107374

hypersensitivity to touch and sound, and depression. At necropsy, observations included reddened and/or darkened lungs, darkened livers, darkened spleens, and fecal-like material in the stomach and GI tract.

Conclusion: Male Rat LD₅₀ = 1700 mg/kg;
Female Rat LD₅₀ = 1200 mg/kg.

17. Acute Dermal Toxicity Test

Stafford albino rabbits were employed in the study. The supplier of rabbits for this test was "Hart-Hill Rabbitry, Howard, Pa. The weight range for the mixed population of male and female rabbits used in the study was 1.342 to 1.839 kg. Five male and five female rabbits had the test material applied to the closely clipped abdominal skin beneath a protective binder. One day later the binder was removed. The test animals were observed for at least 14 days following the initial treatment. Necropsies were performed on all rabbits. The results of this study were that at a single dermal dose of 2000 mg/kg, 1 of the 10 rabbits died within 24 hours. Adverse clinical signs included mild depression and diarrhea. Survivors appeared normal after 2 days. The only local dermal effect was mild-to-moderate erythema following 14 hours of exposure. Necropsy observations for the survivors were normal.

The conclusion for this study is that the acute dermal LD₅₀ > 2000 mg/kg for 90-0221 when tested on a mixed sex population of albino rabbits.

18. Dermal Irritation Study

Stafford albino rabbits were also employed in this study. The primary irritation of the skin was measured by a patch-test technique on the intact skin, where 0.5 ml of the test material was introduced under a 1-inch square adhesive patch. The patch was held in place by adhesive tape and wrapped with rubberized banding for a 14-day period. After 14 hours of exposure, the patches and test material were removed. Readings were taken after 2, 4, 8, 12, 16, and 24 hours. The final score represents an average of all readings. Scoring and evaluation criteria are those described in Table.

As shown in Table, one male and two female rabbits the test material did not produce any erythema, edema or edema at any time point (zero to 24).

It is concluded that 90-0221 LD₅₀ (GI) = 1.05 was a non-irritant to intact skin of six rabbits.

BEST AVAILABLE COPY

IV. Ocular Irritation

Starfished albino rabbits were employed in the study. Eyes of rabbits were examined before application of test material for ocular and perocular abnormalities. Initial examination with fluorescein dye was performed to detect corneal epithelial abnormalities. Rabbits with preexisting ocular lesions or abnormalities were excluded from further ocular testing. In this study, 0.1 ml of test material was placed in the conjunctival sac of the left eye of each of nine (9) rabbits. The treated eye was washed with water 10 to 30 seconds after the exposure in three rabbits with the eyes of the remaining six animals left untreated. The untreated eyes of each rabbit served as control. The cornea, iris, and the bulbar and palpebral conjunctivae were observed at 1, 24, 48, and 72 hours and at 1 and 7 days posttreatment. Observations with fluorescein staining were made at 24 hours after application of the test material and until there was no staining for three consecutive observations. Traize (1965) guidelines were used to assign scores to the observed effects.

In the three rabbits where eyes were washed 10 to 30 seconds after treatment, there was dosing-related mild to moderate conjunctival irritation. All such irritation cleared by day 1. With respect to eyes of those rabbits treated, but left unwashed, SC-3224 410-F (pH 5.85) produced moderate iritis in one rabbit and mild to moderate conjunctival irritation in six rabbits. All irritation cleared by day 7, as confirmed in Tables 1 to 4, pages 15 to 17 (attachments).

Conclusion: Toxicity Category III.

BEST AVAILABLE COPY

14

Td Review 007074

Page _____ is not included in this copy.

Pages 19 through 21 are not included.

The material not included contains the following type of information:

- ☐ Identity of product inert ingredients.
- ☐ Identity of product impurities.
- ☐ Description of the product manufacturing process.
- ☐ Description of quality control procedures.
- ☐ Identity of the source of product ingredients.
- ☐ Sales or other commercial/financial information.
- ☐ A draft product label.
- ☐ The product confidential statement of formula.
- ☐ Information about a pending registration action.
- ☒ FIFRA registration data.
- ☐ The document is a duplicate of page(s) _____.
- ☐ The document is not responsive to the request.

The information not included is generally considered confidential by product registrants. If you have any questions, please contact the individual who prepared the response to your request.

007074

Reviewed By: Brian Ferencik, Ph.D., D.A.P.T.
Section 1, Toxicology Branch I - IRS (TS-7600)
Secondary Reviewer: Edwin P. Rudd, Section Head
Section 1, Toxicology Branch I - IRS (TS-7600)

Study Document 3/6/87
10/89
10/89

DATA EVALUATION REPORT

Study Type: Acute Inhalation Study TSV Cher No.: 8830
Accession No.: 408938-03 EPA ID No.: 476-PFPA
Test Material: SC-0224 4LC-F
Synonyms (Technical Active Ingredient): N-Phosphoromethyl elvoine
tri-ethylsulfonium salt;
SC-0224
Study Number: T-12983
Sponsor: ICI Americas, Inc.
Testing Facility: Stauffer Chemical Company
Farmington, CT
Title of Report: EPA Acute Inhalation Study with SC-0224 4LC-F.
Author(s): S.M. MacAskill and P.A. Grisel
Report Issued: June 22, 1987
Classification: Core - Supplementary
Conclusions:

The study authors report no success in generating a respirable aerosol for acute inhalation testing and, hence, conclude that SC-0224 4LC-F does not pose a threat by inhalation.

According to the study authors, the SC-0224 4LC-F used in the study lacked the physical properties necessary to generate a respirable aerosol for 4 hours. A very small amount of aerosol was visible in the chamber for only a few minutes after starting the generator. The test material property of high viscosity in concert with excessive foaming rendered the generator incapable of producing a satisfactory aerosol with SC-0224 4LC-F. The generator used in this study was a Solosphere® McGaw Respiratory

BEST AVAILABLE COPY

22

007074

therapy, Irvine, CA) nebulizer. The study authors explain that this is the only device that their laboratory has found capable of generating the high concentrations required in acute inhalation studies. The authors also advise that other types of nebulizers (jet, ultrasonic, etc.) would have been of no advantage in dealing with the excessive foaming action of the test material (page 5).

The test protocol which would have been followed in testing this material for inhalation toxicity is attached. Successful pursuit of the protocol would have satisfied the objective of the absence of excessive foaming. Consultation with Toxicology Branch resident expert in inhalational toxicity testing (Dr. Stan Gross) discloses that certain additional effort should be directed toward the evaluation of the test material for inhalational toxicity. The Registrant should be advised to pursue additional testing pending into agreement the following suggestions:

- 1) Dilute the SC-0104 ALC-2 (40% a.i.) with [redacted] until foaming stops.
- 2) Reduce surfactants until foaming stops.
- 3) If necessary, form a dense fog and run through a cyclone separator to remove large particles.
- 4) Consult with Toxicology Branch if testing problems continue.

Attachment

INERT INGREDIENT INFORMATION IS NOT INCLUDED

BEST AVAILABLE COPY

23

Tp. Review 009074

Page _____ is not included in this copy.

Pages 24 through 29 are not included.

The material not included contains the following type of information:

- _____ Identity of product inert ingredients.
- _____ Identity of product impurities.
- _____ Description of the product manufacturing process.
- _____ Description of quality control procedures.
- _____ Identity of the source of product ingredients.
- _____ Sales or other commercial/financial information.
- _____ A draft product label.
- _____ The product confidential statement of formula.
- _____ Information about a pending registration action.
- _____ FIFRA registration data.
- _____ The document is a duplicate of page(s) _____.
- _____ The document is not responsive to the request.

The information not included is generally considered confidential by product registrants. If you have any questions, please contact the individual who prepared the response to your request.

Reviewed By: Brian Parenti, Ph.D., D.A.P.T.
Section I, Toxicology Branch - IPS/HFD (TS-7600)
Secondary Reviewer: Edwin Budd, Section Head
Section I, Toxicology Branch - IPS/HFD (TS-7600)

DATA EVALUATION REPORT

Study Type: Dermal Sensitization Test TOX Chem No.: 8030

Record No.: 035571

VPID No.: 405032-04

Test Substance: SC-0224 4LC-F

Synonyms (technical active ingredient): N-phosphonomethyl
glycine trimethylsulfonium salt: SC-0224

Study Number: T-12588

Sponsor: ICI Americas, Inc.

Testing Facility: Stauffer Chemical Co.
Richmond Toxicology Laboratory
Richmond, CA

Title of Report: "Dermal Sensitization Test
with SC-0224 4 LC-F"

Author: L.C. Vetter

Report issued: 6/2/87

Classification: Core - Guideline

Conclusions: As evaluated by the modified Fustler test procedure,
SC-0224 4 LC-F did not cause dermal sensitization
in the guinea pig. Furthermore, there was no
evidence of an adverse effect of the test mixture
to guinea pigs as measured by weight gain, general
appearance or behavior.

BEST AVAILABLE COPY

30

A. Materials

1. Test Compound

Identification: SC-0224 4IC-F (40.0 wt% of active ingredient)

Description: Brown liquid

Lot No.: JWC 10100-50-1

Purity, Certificates: Unable to locate any additional information on test material purity (this is a formulation for which a Confidential Statement of Formulation exists).

2. Test Animals

Species: Guinea pig

Strain: Hartley

Age: 30-40 days

Weight: 275-400 grams

Source: Charles River Laboratories
Newfield, NJ

B. Study Design - (The following is quoted from pages 9-10 of the study).

"The dermal sensitization potential of SC-0224 4IC-F was tested using a modified Ruebner test according to the Richmond Toxicology Laboratory protocol RTI-DS-7 (Appendix I). Briefly, the modified Ruebner included a primary irritation study, an induction phase (day 1-22), a challenge phase (day 35-39) and a rechallenge phase (day 42-45).

"Eight animals were used in the primary irritation phase. A 3% solution of SC-0224 4IC-F in distilled water was applied to the shaved right flank of all the animals. Observations of skin responses were made at 24, 48 and 72 hours following the initial application. One week later, SC-0224 4IC-F was applied neat to the animals shaved left flank. Skin responses were again evaluated at 24, 48 and 72 hours following the initial application.

"There were three groups of guinea pigs (n=10) in the induction and challenge phases. One group served as the Test Group and was induced, challenged and rechallenged with SC-0224 4IC-F. Another group, the Negative Control Group, was induced with saline and challenged/rechallenged with SC-0224 4IC-F.

BEST AVAILABLE COPY

31

007074

The Positive Control Group was induced, challenged and re-challenged with 0.1% DNCB. Each animal was concurrently challenged with the appropriate challenge vehicle and, in effect, served as its own control.

All materials were applied topically (in a volume of 0.5 ml.) occluded and left on the skin for six hours. Liquids were applied to a 2.5 or 4-centimeter diameter without adhesive, placed on the skin and secured by wrapping the abdomen with gauze. Induction applications were made to the shaved right flank on alternate days (Monday, Wednesday, and Friday, starting on Wednesday), for a total of ten applications. Induction applications were made to the shaved right flank. Two weeks after the last induction application, each animal was challenged on the test material and the vehicle. All animals were re-challenged one week later on the shaved and depilated upper left flank with concurrent applications of the test material and the vehicle. To minimize variations in response to flank location, the application site sequence of test material and vehicle were reversed for half of the animals of each group. The skin reactions were evaluated for erythema (redness) and edema (swelling) according to a 4-point scoring system (Table 1). Other responses, e.g., skin flaking, eschar, induration, etc., were also noted if present but were not included in the score. Eschar is defined in this test as clear or colored exudate or injuries in depth. These evaluations were made on Tuesdays and Thursdays during induction and daily for the 3 days following challenge/rechallenge and primary irritation applications.

A known sensitizer, dinitro-chlorobenzene (DNCB), was used as the positive control material. DNCB was dissolved in 70% ethanolic water for induction and acetone for the challenge and rechallenge. The change in DNCB vehicles was made to optimize the induction of sensitized animals and prevent the possibility of ethanol sensitization. SC-021-LIC-3 was applied neat for the induction challenge and rechallenge phases, and for purposes of this test, saline will be considered as the vehicle for SC-0224 LIC-3.

Positive control material dose solutions were analyzed by UV spectrophotometry according to the Richmond Toxicology Laboratory protocol PTL-AN-1 (Appendix VII).

A group was considered to have a positive response if one or more animals in the group exhibited an erythema or edema score of 2 or greater. The material was considered to be a sensitizer if the challenge reaction was positive, persistent and greater than the irritation reaction. Irritation was determined from the primary irritation results and the challenge response of the Negative Control Group."

BEST AVAILABLE COPY

32

C. Results

With the exception of skin flaking noted for three animals at certain time points during the induction phase among the SC-0224 410-E group and also for several animals of both SC-0224 410-E and saline controls during the challenge phase, no adverse effects were produced by SC-0224 410-E in this study. There were no deaths. The test material did not produce any effects or weight gain of animals during the study. However, the positive control (DNCP) group gained more weight than the control group, an effect which appeared to be manifested only during week 7, the final week of observation. This seems to be a questionable change since it was so marked during week 7 without any evidence of a positive control effect up to week 7. (Table 2, p. 16)

SC-0224 410-E test results do not reveal any evidence that the material elicited erythema or edema during the induction phase (Table 4, p. 16).

As to the principal objective of this study, which was to determine whether SC-0224 410-E causes dermal sensitization, there was no evidence of a positive response either during the first challenge (Table 5, p. 19) or during the rechallenge phase of the study (Table 6, p. 20). By contrast, the positive control substance, DNCP, elicited positive responses during both the first challenge and rechallenge phases. Inspection of individual animal test data as displayed in Appendices II-IV, pp. 39-47 of the study, confirm the tabulated findings.

(Attachments: Tables 4, 5 and 6, pp. 18-20 of the study)

BEST AVAILABLE COPY

33

TABLE 4

SUMMARY OF INDUCTION PHASE RESULTS

EXPERIMENTAL GROUP	SKIN RESPONSE	DAY NUMBER					
		2	7	9	14	16	21
TEST MATERIAL (SC-0224 4LC-E)	ERYTHEMA	SCORE ^a FREQUENCY ^b	0 0/10	0 0/10	0 0/10	0 0/10	0 0/10
	EDEMA	SCORE FREQUENCY	0 0/10	0 0/10	0 0/10	0 0/10	0 0/10
NEGATIVE CONTROL (Saline)	ERYTHEMA	SCORE FREQUENCY	0 0/10	0 0/10	0 0/10	0 0/10	0 0/10
	EDEMA	SCORE FREQUENCY	0 0/10	0 0/10	0 0/10	0 0/10	0 0/10
POSITIVE CONTROL (0.1% DNCB)	ERYTHEMA	SCORE FREQUENCY	0 0/10	1.3 9/10	1.6 8/10	1.8 9/10	1.9 10/10
	EDEMA	SCORE FREQUENCY	0 0/10	0 0/10	0 0/10	0 0/10	0 0/10

^a AVERAGE SCORE OF RESPONSES ≥ 1
^b FREQUENCY OF RESPONSE SCORES ≥ 1

BEST AVAILABLE COPY

34

007017

TABLE 5
SUMMARY OF FIRST CHALLENGE RESULTS

EXPERIMENTAL GROUP	SKIN RESPONSE	HOURS AFTER FIRST CHALLENGE APPLICATION					
		24			48		
		TMC	VO	TM	V	TM	V
TEST MATERIAL (SC-0224 4LC-E)	ERYTHEMA	0	0	0	0	0	0
	FREQUENCY ^b	0/10	0/10	0/10	0/10	0/10	0/10
	EDLEMA	0	0	0	0	0	0
	FREQUENCY	0/10	0/10	0/10	0/10	0/10	0/10
NEGATIVE CONTROL (0.85% Saline)	ERYTHEMA	0	0	0	0	0	0
	FREQUENCY	0/10	0/10	0/10	0/10	0/10	0/10
	EDLEMA	0	0	0	0	0	0
	FREQUENCY	0/10	0/10	0/10	0/10	0/10	0/10
POSITIVE CONTROL (0.1% DNCB)	ERYTHEMA	1.9	0	2.0	0	2.0	0
	FREQUENCY	10/10	0/10	10/10	0/10	8/10	0/10
	EDLEMA	1.8	0	2.0	0	0	0
	FREQUENCY	9/10	0/10	8/10	0/10	0/10	0/10

a AVERAGE SCORE FOR RESPONSES > 1
b FREQUENCY OF RESPONSE SCORES > 1
c TM - TEST MATERIAL OR DNCB SITE
d V - VEHICLE SITE

BEST AVAILABLE COPY

007074

35

007074

TABLE 6
SUMMARY OF RECHALLENGE RESULTS

EXPERIMENTAL GROUP	SKIN RESPONSE	HOURS AFTER FIRST CHALLENGE APPLICATION					
		24		48		72	
		TMC	VD	TM	V	TM	V
TEST MATERIAL (SC-0224 4LC-E)	ERYTHEMA	0	0	0	0	0	0
	FREQUENCY ^b	0/10	0/10	0/10	0/10	0/10	0/10
NEGATIVE CONTROL (0.85% Saline)	EDEMA	0	0	0	0	0	0
	FREQUENCY	0/10	0/10	0/10	0/10	0/10	0/10
	ERYTHEMA	0	0	0	0	0	0
	FREQUENCY	0/10	0/10	0/10	0/10	0/10	0/10
	EDEMA	0	0	0	0	0	0
	FREQUENCY	0/10	0/10	0/10	0/10	0/10	0/10
POSITIVE CONTROL (0.1% DNCB)	ERYTHEMA	2.1	0	1.9	0	1.7	0
	FREQUENCY	10/10	0/10	10/10	0/10	10/10	0/10
	EDEMA	2.3	0	2.7	1.0	1.0	0
	FREQUENCY	3/10	0/10	7/10	1/10	8/10	0/10

a AVERAGE SCORE FOR RESPONSES > 1
b FREQUENCY OF RESPONSE SCORES > 1
c TM = TEST MATERIAL OR DNCB SITE
d V = VEHICLE SITE

BEST AVAILABLE COPY

36